{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "cacm-regulation", "type": "definition", "offset": [75, 90]}], "samples": [{"hash": "awtdmVPviMA", "uri": "https://eepublicdownloads.entsoe.eu/clean-documents/nc-tasks/ACER_Decision_03-2024%20MERGED2.pdf", "label": "Amendment", "score": 23.1360836029, "published": false}, {"hash": "l8q3MixmfuH", "uri": "https://eepublicdownloads.entsoe.eu/clean-documents/nc-tasks/ACER_Decision_03-2024_2-3_amendment_Core_Intraday_CCM%20MERGED.pdf", "label": "Amendment", "score": 23.0705280304, "published": false}, {"hash": "caWBFkOCFFa", "uri": "https://www.acer.europa.eu/sites/default/files/documents/Individual%20Decisions_annex/ACER_Decision_03-2024_Core_ID_CCM_A2-Annex_Ia.pdf", "label": "Amendment", "score": 22.8773231506, "published": false}], "size": 58, "snippet": "or \u2018\ud835\udc3a\ud835\udc46\ud835\udc3e\u2019 means the generation shift key as defined in Article 2(12) of the CACM Regulation;", "hash": "83a7ff84a472a9ca9381044952cc0e92", "id": 1}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}], "samples": [{"hash": "aTvTZsnyvdS", "uri": "/contracts/aTvTZsnyvdS#gsk", "label": "Research, Collaboration and License Agreement (Camp4 Therapeutics Corp)", "score": 37.1724845996, "published": true}, {"hash": "jgq6QxC8gvV", "uri": "/contracts/jgq6QxC8gvV#gsk", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 35.2012329102, "published": true}, {"hash": "4BqtFdMM7TS", "uri": "/contracts/4BqtFdMM7TS#gsk", "label": "Exclusive License Agreement (Scynexis Inc)", "score": 34.3524971008, "published": true}], "size": 38, "snippet": "has the meaning set forth in the preamble.", "hash": "550c6397310458225d7327158d62c082", "id": 2}, {"snippet_links": [{"key": "gsk-plc", "type": "definition", "offset": [6, 13]}, {"key": "limited-company", "type": "clause", "offset": [24, 39]}, {"key": "registered-office", "type": "clause", "offset": [97, 114]}], "samples": [{"hash": "9UaU0VoBKgf", "uri": "/contracts/9UaU0VoBKgf#gsk", "label": "Exchange Agreement (Haleon PLC)", "score": 33.4134140015, "published": true}, {"hash": "UJgArgLE3d", "uri": "/contracts/UJgArgLE3d#gsk", "label": "Exchange Agreement (Haleon PLC)", "score": 33.3915138245, "published": true}, {"hash": "94tElOgdiFg", "uri": "/contracts/94tElOgdiFg#gsk", "label": "Exchange Agreement (Haleon PLC)", "score": 33.3531837463, "published": true}], "size": 9, "snippet": "means GSK plc, a public limited company incorporated in England with number 03888792, having its registered office at \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587 \u2587\u2587\u2587;", "hash": "65376491e93e456344f70782b406d605", "id": 3}, {"snippet_links": [{"key": "glaxosmithkline-plc", "type": "clause", "offset": [6, 25]}], "samples": [{"hash": "372jzYMvzB7", "uri": "/contracts/372jzYMvzB7#gsk", "label": "Share and Business Sale Agreement (Novartis Ag)", "score": 24.0704994202, "published": true}, {"hash": "7Jqj9SXieBK", "uri": "https://www.sec.gov/Archives/edgar/data/1114448/000104746916009872/a2227040zex-4_7.htm", "label": "Share and Business Sale Agreement (Novartis Ag)", "score": 17.069814682, "published": false}], "size": 8, "snippet": "means GlaxoSmithKline plc and its Affiliates;", "hash": "6e079743c04f70812caa35d3e3365746", "id": 4}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [36, 48]}, {"key": "this-agreement", "type": "clause", "offset": [52, 66]}], "samples": [{"hash": "lLeE4Zpuim", "uri": "/contracts/lLeE4Zpuim#gsk", "label": "Respiratory Diseases Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 24.622177124, "published": true}, {"hash": "fMMVnHcAB00", "uri": "/contracts/fMMVnHcAB00#gsk", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 24.622177124, "published": true}, {"hash": "j20yEdcksds", "uri": "/contracts/j20yEdcksds#gsk", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 24.5646820068, "published": true}], "size": 7, "snippet": "shall have the meaning set forth in the preamble of this Agreement.", "hash": "cd07e308b97b07007b4e877c75d5e4a6", "id": 5}, {"snippet_links": [{"key": "cacm-regulation", "type": "definition", "offset": [64, 79]}], "samples": [{"hash": "6r9uHJpq8lJ", "uri": "https://consultations.entsoe.eu/markets/core-lt-ccm/supporting_documents/Core%20LT%20CCM%201st%20RfA%20%20Track%20change2.pdf", "label": "First Amendment", "score": 21.9975776672, "published": false}, {"hash": "8m0fR9NC8Ju", "uri": "https://eepublicdownloads.entsoe.eu/clean-documents/nc-tasks/ACER%202nd%20decision%20and%20annexes.pdf", "label": "eepublicdownloads.entsoe.eu", "score": 10.9356603622, "published": false}, {"hash": "4DHJZxfFCSr", "uri": "https://acer.europa.eu/sites/default/files/documents/Individual%20Decisions_annex/ACER_Decision_03-2023_Core_LT_CCM-AnnexI.pdf", "label": "acer.europa.eu", "score": 9.5229291916, "published": false}], "size": 6, "snippet": "means: Generation Shift Key, as defined in Article 2(12) of the CACM Regulation;", "hash": "6d499e27afa21edc46cf119253ec205e", "id": 6}, {"snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [48, 60]}], "samples": [{"hash": "krQywsjwAFz", "uri": "/contracts/krQywsjwAFz#gsk", "label": "Exclusive License and Nonexclusive Option Agreement", "score": 31.3408622742, "published": true}, {"hash": "jXarcyyTxOx", "uri": "/contracts/jXarcyyTxOx#gsk", "label": "Product Development and Commercialization Agreement (Regulus Therapeutics Inc.)", "score": 23.7132110596, "published": true}, {"hash": "ivAHzNNS0Ng", "uri": "/contracts/ivAHzNNS0Ng#gsk", "label": "Exclusive License and Nonexclusive Option Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}], "size": 6, "snippet": "shall have the meaning assigned to such term in the Recitals.", "hash": "7cec9491c1156ce5e41855069617ecb5", "id": 7}, {"snippet_links": [{"key": "company-limited", "type": "clause", "offset": [37, 52]}, {"key": "england-and-wales", "type": "clause", "offset": [92, 109]}], "samples": [{"hash": "5WtJrl8Oihd", "uri": "/contracts/5WtJrl8Oihd#gsk", "label": "Limited Liability Company Agreement", "score": 31.3408622742, "published": true}, {"hash": "h3uUCrvI4ws", "uri": "/contracts/h3uUCrvI4ws#gsk", "label": "Limited Liability Company Agreement (Theravance Inc)", "score": 25.4243659973, "published": true}, {"hash": "jADGU2htmKl", "uri": "/contracts/jADGU2htmKl#gsk", "label": "Limited Liability Company Agreement (Theravance Inc)", "score": 25.3011627197, "published": true}], "size": 6, "snippet": "means Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales.", "hash": "a3a8f4e502228c5118e0568ec928a939", "id": 8}, {"snippet_links": [{"key": "first-paragraph", "type": "definition", "offset": [45, 60]}, {"key": "this-agreement", "type": "clause", "offset": [64, 78]}], "samples": [{"hash": "czSgpFyrqkq", "uri": "/contracts/czSgpFyrqkq#gsk", "label": "License and Collaboration Agreement (Amicus Therapeutics, Inc.)", "score": 35.1574249268, "published": true}, {"hash": "8UxVxjNqGmy", "uri": "/contracts/8UxVxjNqGmy#gsk", "label": "Restated Agreement", "score": 31.3408622742, "published": true}, {"hash": "b6xu7disJBB", "uri": "/contracts/b6xu7disJBB#gsk", "label": "Licensing, Development, Manufacturing and Marketing Agreement", "score": 27.0396995544, "published": true}], "size": 6, "snippet": "has the meaning ascribed to that term in the first paragraph of this Agreement.", "hash": "009bd5b08def631f7bc0b75ed790a306", "id": 9}, {"snippet_links": [{"key": "in-the-agreement", "type": "clause", "offset": [21, 37]}], "samples": [{"hash": "j02KvuFtwed", "uri": "/contracts/j02KvuFtwed#gsk", "label": "Covid Cla Third Amendment and Restatement Agreement (CureVac N.V.)", "score": 33.3203277588, "published": true}, {"hash": "fyU9yu51jLI", "uri": "/contracts/fyU9yu51jLI#gsk", "label": "Fourth Amendment and Restatement Agreement (CureVac N.V.)", "score": 33.3203277588, "published": true}, {"hash": "fyRsltWnB86", "uri": "/contracts/fyRsltWnB86#gsk", "label": "2020 Cla Amendment and Restatement Agreement (CureVac N.V.)", "score": 32.3182754517, "published": true}], "size": 6, "snippet": "means GSK as defined in the Agreement and its Affiliates.", "hash": "e3b2b44f1109b2e0bf332220c7c0149d", "id": 10}], "next_curs": "ClASSmoVc35sYXdpbnNpZGVyY29udHJhY3RzciwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIMZ3NrIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "GSK", "size": 287, "snippet": "or \u2018\ud835\udc3a\ud835\udc46\ud835\udc3e\u2019 means the generation shift key as defined in Article 2(12) of the CACM Regulation;", "id": "gsk", "examples": ["Following the Effective Date, <strong>GSK</strong>, as the Party responsible for achieving each Development Milestone Event, shall notify CAMP4 within [***] following the achievement of a given Development Milestone Event by <strong>GSK</strong> or any of its Affiliates or Sublicensees, as applicable, and the corresponding Development Milestone Payment shall be due within [***] following [***] after <strong>GSK</strong>\u2019s receipt of a Valid Invoice in accordance with Section 6.6 for such Development Milestone Payment.", "Except as otherwise permitted under applicable Law, <strong>GSK</strong> will not practice the Licensed Intellectual Property other than as expressly licensed and permitted under this Agreement.", "At any time during the Term, <strong>GSK</strong> may, at its convenience, terminate this Agreement (a) in its entirety; or (b) on a Collaboration Target-by-Collaboration Target basis, in each case, upon [***] prior written notice to CAMP4.", "As between the Parties, (A) <strong>GSK</strong> will solely and exclusively own and retain all right, title and interest in and to all <strong>GSK</strong> Background Technology; and (B) subject to the rights and licenses granted to <strong>GSK</strong> under this Agreement, CAMP4 will solely and exclusively own and retain all right, title and interest in and to all CAMP4 Background Technology.", "All rights in and to Licensed Intellectual Property not expressly licensed or otherwise granted to <strong>GSK</strong> under this Agreement are hereby retained by CAMP4 (or its Affiliates, as applicable).", "During the Term, (i) CAMP4 will promptly disclose to <strong>GSK</strong> all CAMP4 Arising Intellectual Property and all [***]; and (ii) each Party will promptly disclose to the other Party all Joint Arising Intellectual Property, in each case (i) and (ii), including all invention disclosures or other similar documents and applications relating thereto.", "Activities conducted by <strong>GSK</strong>\u2019s Affiliates or any of their respective Sublicensees and subcontractors will be considered as <strong>GSK</strong>\u2019s activities under this Agreement for purposes of determining whether <strong>GSK</strong> has complied with its obligation to use Commercially Reasonable Efforts.", "All rights in and to any Know-How, Patents or other intellectual property rights owned or otherwise controlled by <strong>GSK</strong> or its Affiliates not expressly licensed or otherwise granted to CAMP4 under this Agreement are hereby retained by <strong>GSK</strong> (or its Affiliates, as applicable).", "CAMP4 shall (and shall cause its Affiliates to) cooperate fully with, and at <strong>GSK</strong>\u2019s request work directly with, any such Third Party subcontractor with respect to the performance of any of <strong>GSK</strong>\u2019s activities under any Research Plan allocated to such subcontractor by <strong>GSK</strong>.", "As between the Parties, <strong>GSK</strong> shall have the sole and exclusive right, at its option and in its sole discretion, to control the clearance, filing, prosecution, and maintenance of all <strong>GSK</strong> Trademarks in the Territory, at its sole cost and expense."], "related": [["bms", "BMS", "BMS"], ["novartis", "Novartis", "Novartis"], ["merck", "Merck", "Merck"], ["isis", "ISIS", "ISIS"], ["pfizer", "Pfizer", "Pfizer"]], "related_snippets": [], "updated": "2026-03-07T04:27:53+00:00"}, "json": true, "cursor": ""}}